Navigation Links
Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:12/16/2010

SAN DIEGO, Dec. 16, 2010 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 12, 2011. Pedro Lichtinger, Optimer's President and Chief Executive Officer, will present at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time).

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

A live audio webcast of this presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com. Replays of this presentation will be available at the same location for 30 days following the meeting.

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, Fidaxomicin and Pruvel™ (prulifloxacin).  Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI).  The Company has submitted an NDA to the FDA, and filed a MAA with the EMA (Europe) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer & VP Finance858-909-0736Canale CommunicationsJason I. Spark, Senior Vice President619-849-6005
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference
2. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
3. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
4. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
5. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
6. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
7. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
8. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
9. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
10. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
11. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... January 13, 2017 , ... Two Kalamazoo ... compound called fulvic acid that farms, greenhouses and hydroponics operations use to increase ... among the fastest growing segments of customers using this high grade fulvic acid ...
(Date:1/12/2017)... ... 2017 , ... Each year, Crain’s Detroit Business News ranks the most innovative ... patent estate of a company, its impact and significance, and the likelihood of bringing ... in technologies that transform energy sources such as low dose X-ray and convert them ...
(Date:1/12/2017)... DC , January 12, 2017 ... up the world,s biggest facility for producing mycorrhizae. The ... the nutrient tapping potential of mycorrhizae and developed a ... ... (Logo: http://mma.prnewswire.com/media/456932/PRNE_TERI_Logo.jpg) The TERI facility ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... of Limfinity® Cloud, RURO has enhanced the platform to accommodate increasingly complex ... login, rapid data searching, and more. In addition to these improvements, the ...
Breaking Biology Technology:
(Date:12/15/2016)... --  WaferGen Bio-systems, Inc. (NASDAQ: WGBS ... that on December 13, 2016, it received a letter ... Market LLC which acknowledged that, as of December 12, ... had been at $1.00 or greater for ten consecutive ... Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/15/2016)... LONDON , Dec. 14, 2016 "Increase ... mobile biometrics market" The mobile biometrics market is expected ... USD 49.33 billion by 2022, at a CAGR of ... by factors such as the growing demand for smart ... mobile transactions. "Software component is expected to ...
(Date:12/7/2016)... -- According to a new market research report "Emotion Detection and ... Recognition), Service, Application Area, End User, And Region - Global Forecast to 2021", ... Billion in 2016 to USD 36.07 Billion by 2021, at a Compound Annual ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):